Duggirala Aparna, Delogu Francesca, Angelini Timothy G, Smith Tanya, Caputo Massimo, Rajakaruna Cha, Emanueli Costanza
Bristol Heart Institute, School of Clinical Sciences, University of Bristol Bristol, UK.
Royal Surrey County Hospital Guildford, UK.
Front Genet. 2015 Apr 1;6:125. doi: 10.3389/fgene.2015.00125. eCollection 2015.
An aneurysm is a local dilatation of a vessel wall which is >50% its original diameter. Within the spectrum of cardiovascular diseases, aortic aneurysms are among the most challenging to treat. Most patients present acutely after aneurysm rupture or dissection from a previous asymptomatic condition and are managed by open surgical or endovascular repair. In addition, patients may harbor concurrent disease contraindicating surgical intervention. Collectively, these factors have driven the search for alternative methods of identifying, monitoring and treating aortic aneurisms using less invasive approaches. Non-coding RNA (ncRNAs) are emerging as new fundamental regulators of gene expression. The small microRNAs have opened the field of ncRNAs capturing the attention of basic and clinical scientists for their potential to become new therapeutic targets and clinical biomarkers for aortic aneurysm. More recently, long ncRNAs (lncRNAs) have started to be actively investigated, leading to first exciting reports, which further suggest their important and yet largely unexplored contribution to vascular physiology and disease. This review introduces the different ncRNA types and focus at ncRNA roles in aorta aneurysms. We discuss the potential of therapeutic interventions targeting ncRNAs and we describe the research models allowing for mechanistic studies and clinical translation attempts for controlling aneurysm progression. Furthermore, we discuss the potential role of microRNAs and lncRNAs as clinical biomarkers.
动脉瘤是血管壁的局部扩张,其直径大于原始直径的50%。在心血管疾病范围内,主动脉瘤是最难治疗的疾病之一。大多数患者在动脉瘤破裂或从前无症状状态发生夹层后急性就诊,并通过开放手术或血管内修复进行治疗。此外,患者可能同时患有禁忌手术干预的疾病。总体而言,这些因素促使人们寻找使用侵入性较小的方法来识别、监测和治疗主动脉瘤的替代方法。非编码RNA(ncRNAs)正在成为基因表达的新的基本调节因子。小的微小RNA开启了ncRNAs领域,因其有可能成为主动脉瘤的新治疗靶点和临床生物标志物而吸引了基础和临床科学家的关注。最近,长链ncRNAs(lncRNAs)已开始受到积极研究,产生了首批令人兴奋的报告,这进一步表明它们对血管生理和疾病有着重要但在很大程度上尚未被探索的作用。本综述介绍了不同类型的ncRNAs,并重点关注ncRNAs在主动脉瘤中的作用。我们讨论了针对ncRNAs的治疗干预的潜力,并描述了用于进行机制研究和临床转化尝试以控制动脉瘤进展的研究模型。此外,我们还讨论了微小RNA和lncRNAs作为临床生物标志物的潜在作用。